GSK's Strategic Shift: New CEO Luke Miels Eyes 2026

GSK forecasts slower sales growth for 2026 as new CEO Luke Miels shifts focus to expanding the drug pipeline amid patent expiries for its leading HIV drugs. With aims for significant sales growth by 2031, Miels faces challenges in commercial execution and policy as patents near expiration.

GSK's forecast for a slower sales growth in 2026 marks a strategic pivot under new CEO Luke Miels, targeting pipeline expansion to mitigate the impact of expiring patents on top-selling HIV medications.

The company's roadmap, setting to transition from research ramp-up to commercial execution, is crucial to achieving its ambitious goal of over 40 billion pounds in sales by 2031.

As Miels leads GSK through tariff dynamics and patent expirations, 2026 is deemed pivotal for operational execution, with projections for a 7%-9% rise in core earnings per share.

(With inputs from agencies.)